The ALLHAT and the cardioprotection conferred by diuretics in hypertensive patients: A connection with uric acid?

Cardiovascular Drugs and Therapy

Volumn 16, Issue 6, 2002, Pages 485-487

  Reyes, Ariel J ^a   Leary, William P ^b  

^a Institute of Cardiovascular Theory Montevideo   (Uruguay)

^b UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ANTAGONIST; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; URIC ACID;

BLOOD PRESSURE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DOSE RESPONSE; EDITORIAL; HEART PROTECTION; HUMAN; HYPERTENSION; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR;

EID: 0036993602     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/a:1023090823731     Document Type: Editorial

References (33)

1. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-2997.
2. Leary WP, Reyes AJ. Angiotensin I converting enzyme inhibitors and the renal excretion of urate. Cardiovasc Drugs Ther 1987;1:29-38.
3. Johnson MW, Mitch WE. The risks of asymptomatic hyperuricemia and the use of uricosuric diuretics. Drugs 1981;2:220-225.
4. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality in the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 2000;283:2404-2410.
5. Sakata K, Hashimoto T, Ueshima H, Okayama A, NIPPON DATA 80 Research Group. Absence of an association between serum uric acid and mortality from cardiovascular disease: NIPPON DATA 80, 1980-1994. National Integrated Projects for Prospective Observation of Non-communicable Diseases and its Trend in the Aged. Eur J Epidemiol 2001;17:461-468.
6. Cappuccio FP, Strazzullo P, Siani A, Trevisan M. Increased proximal sodium reabsorption is associated with increased cardiovascular risk in man. J Hypertens 1996;14:909-914.
7. Modan M, Halkin H, Karasik A, Lusky A. Elevated serum uric acid - A facet of hyperinsulinemia. Diabetologia 1987;30:713-718.
8. Nakanishi N, Tatara K, Nakamura K, Suzuki K. Risk factors for the incidence of hyperuricaemia: A 6-year longitudinal study of middle-aged Japanese men. Int J Epidemiol 1999;28:888-893.
9. Cappuccio FP, Strazzullo P, Farinaro E, Trevisan M. Uric acid metabolism and tubular Sodium handling. JAMA 1993;270:354-359.
10. Strazzullo P, Barba G, Siani A, et al. Enhanced proximal tubular sodium reabsorption is associated with hypertension in men independently of age and body mass (Abstract). J Hypertens 2002;20(suppl 4):S252.
11. Tykarski A. Evaluation of renal handling of uric acid in essential hypertension: Hyperuricemia related to decreased urate secretion. Nephron 1991;59:364-368.
12. Lucchesi BR. Free radicals and tissue injury. Dial Cardiovasc Med 1998;3:3-22.
13. Skinner KA, White CR, Patel R, et al. Nitrosation of uric acid by peroxynitrite. Formation of a vasoactive nitric oxide donor. J Biol Chem 1998;273:24491-24497.
14. Whiteman M, Ketsawatsakul U, Halliwell B. A reassessment of the peroxynitrite scavenging activity of uric acid. Ann NY Acad Sci 2002;962:242-259.
15. Johnson WD, Kayser KL, Brenowitz JB, Saedi SF. A randomized controlled trial of allopurinol in coronary bypass surgery. Am Heart J 1991;121:20-24.
16. Doehner W, Schoene N, Rauchhaus M, et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: Results from 2 placebo-controlled studies. Circulation 2002;105:2619-2624.
17. Waring WS, Webb DJ, Maxwell SR. Systemic uric acid administration increases serum antioxidant capacity in healthy volunteers. J Cardiovasc Pharmacol 2001;38:365-371.
18. Chamorro A, Obach V, Cervera A, Revilla M, Deulofeu R, Aponte JH. Prognostic significance of uric acid serum concentration in patients with acute ischemic stroke. Stroke 2002;33:1048-1052.
19. Squadrito GL, Cueto R, Splenser AE, et al. Reaction of uric acid with peroxynitrite and implications for the mechanism of neuroprotection by uric acid. Arch Biochem Biophys 2000;376:333-337.
20. Ward NC, Croft KD, Hodgson JM, Beilin LJ, Puddey IB. A case control comparison of total antioxidant capacity of plasma in treated and untreated hypertensive subjects (Abstract). J Hypertens 2002;20(suppl 4):S107.
21. Reyes AJ. Diuretics in the therapy of hypertension. J Hum Hypertens 2002;16(suppl 1):S78-S83.
22. Scholze J, for the East Germany Collaborative Trial Group, Breitstadt A, Cairns V, et al. Ramipril and hydrochlorothiazide combination therapy in hypertension: A clinical trial of factorial design. J Hypertens 1993;11(suppl 2):S25-S33.
23. MacKay JH, Arcuri KE, Goldberg Al, Snapinn SM, Sweet CS. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. Arch Intern Med 1996;156:278-285.
24. Kochar M, Guthrie R, Triscari J, Kassler-Taub K, Reeves RA. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. Am J Hypertens 1999;12: 797-805.
25. Korduner Y, Käbin I, Hagbarth G. Low-dose chlorthalidone treatment in previously untreated hypertension. Curr Ther Res Clin Exp 1981;29:208-215.
26. Pollavini G, Comi D, Grillo C, et al. Multicentre randomized cross-over double-blind comparison between chlorthalidone and slow-release oxprenolol in mild-to-moderate hypertension. Curr Therap Res Clin Exp 1984;35:465-475.
27. Franse LV, Pahor M, Di Bari M, et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens 2000;18:1149-1154.
28. Carlsen JE, Kober L, Torp-Pedersen C, Johansen P. Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. Br Med J 1990;300:975-978.
29. Girvin B, Johnston GD. A randomized comparison of a conventional dose, a low dose and alternate-day dosing of bendrofluazide in hypertensive patients. J Hypertens 1998;16:1049-1054.
30. Hashida JG. A double-blind multicentre study of indapamide in the treatment of essential hypertension. Curr Med Res Opin 1977;5(suppl I):116-123.
31. Reyes AJ. Uric acid in cardiovascular diseases and the uricosuric and hypouricaemic actions of angiotensin-converting enzyme inhibitors. In: Reyes AJ, Maranhão MFC, eds. Cardiovascular Pharmacotherapy. Proceedings of the 9th International Congress on Cardiovascular Pharmacotherapy. Bologna: Monduzzi Editore, 2000:235-240.
32. Reyes AJ, Leary WP, van der Byl K. Renal excretory responses to single and repeated administration of loop and of distal tubular diuretics at various doses in healthy man. Prog Pharmacol Clin Pharmacol 1992;9:219-262.
33. Fotherby MD, Potter JF. Metabolic and orthostatic blood pressure responses to a low-sodium diet in elderly hypertensives. J Hum Hypertens 1997;11:361-366.